Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DLX105 in Fistulizing Crohn's Disease
NCT01624376Phase 2Completed
- Sponsor
- Delenex Therapeutics
- Start
- Jun 2012
- Primary completion
- Feb 2013
- Modality
- Antibody Conjugates, scFv Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing DLX105 with Placebo Injection (2 arms). Primary endpoints: Local Tolerability at 4 weeks and Reduction of Number of draining fistulas at Day 43. Started Jun 2012; status: completed.
02
Drugs
DLX105
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01624376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01624376.